McKesson Corporation

MCK · NYSE · USD

Analysis

Last 4 earnings calls · through Q1 FY2027

McKesson's profit now comes from a small slice of its revenue: oncology and biopharma services grew double digits again while distribution was squeezed by drug-price cuts. Guidance went up again, and the medical-surgical split is paying for buybacks. How much of total profit now comes from oncology and biopharma services?

  • The two small segments are now the growth engine.

    Oncology and multispecialty grew 24% in Q1 FY2027 excluding the Core Ventures purchase, and the network added 570 providers last year. Each one brings distribution, drug purchasing and data with it, so one win pays off in several ways. How much of oncology's growth came from acquisitions versus existing practices?

  • Drug-price cuts shrink the top line, not the profit.

    In Q4 FY2026 branded price cuts trimmed North American Pharmaceutical revenue by about 3%, yet operating profit still grew. McKesson is paid a fee for handling a drug, not a share of its price, so the cuts cost the business almost nothing.

  • The growth businesses must spend before they earn.

    Prescription Technology Solutions is guided to barely grow revenue in FY2027 while profit rises several times faster. The extra distribution spending lands in the second half and pays back at the start of FY2028. What does the second-half spending do to FY2027 profit growth?

Bullish
  • Specialty and oncology platform
    The bull case rests on oncology and multispecialty, where McKesson keeps adding providers and layers services onto distribution so each relationship earns more.
  • Biopharma access services
    Biopharma services add technology revenue on top of distribution, and demand for prior authorization and affordability tools keeps bringing new brands onto the platform.
  • Operating leverage on thin margins
    Because distribution margins are thin, small gains in expense efficiency and generic sourcing fall straight to profit, and management has raised its outlook each quarter.
Bearish
  • Customer concentration
    The bear case is that a handful of retail and health-system customers generate most of the revenue and can press for better terms as they consolidate.
  • Branded drug price declines
    Branded manufacturers keep cutting list prices and shifting to generics, so reported revenue shrinks and profit has to come from volume and cost instead of price.
  • Medical-Surgical separation
    Separating Medical-Surgical absorbs management attention and balance-sheet capacity while the retained majority stake keeps a slower-growing business in the numbers.
See the full bull & bear case
PoliticiansInstitutionsInsiders
PoliticianTransactionAmountTradedFiled
Donald Trump
Republican · Executive
Purchase≥$100KJun 12Aug 22
Donald Trump
Republican · Executive
Sale≥$1KMay 18Jul 1
Donald Trump
Republican · Executive
Sale≥$100KMay 11Jul 1
Donald Trump
Republican · Executive
Purchase≥$1KMar 23May 13
Ro Khanna
Democratic · House · CA-17
Purchase≥$1KAug 10Sep 4

Congressional trading data provided by QuiverQuant

See all
Product segmentsGeography
FY2026 · USD

How McKesson turned $403B of revenue into $6.2B of operating income.

Revenue
North American Pharmaceutical Segment$337B
Oncology And Multispecialty Segment$48.4B
Medical-Surgical Solutions Segment$11.5B▲ 1.06% YoY
Prescription Technology Solutions Segment$5.8B
Reconciling items$1.0B
Total revenue$403B
Gross profit$14.6B3.6%
Operating income$6.2B1.5%
See all